Neurocrine Biosciences
NBIX
#1313
Rank
HK$134.70 B
Marketcap
HK$1,340
Share price
-0.39%
Change (1 day)
29.48%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2026 (TTM): HK$52.40

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is HK$52.61. In 2025 the company made an earnings per share (EPS) of HK$37.79 an increase over its 2024 EPS that were of HK$26.50.

EPS history for Neurocrine Biosciences from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)HK$52.4038.67%
2025HK$37.7942.6%
2024HK$26.5033.07%
2023HK$19.9157.76%
2022HK$12.6269.47%
2021HK$7.45-78.21%
2020HK$34.18990%
2019HK$3.1481.82%
2018HK$1.72-113.5%
2017-HK$12.780.62%
2016-HK$12.7057.28%
2015-HK$8.0725.61%
2014-HK$6.4318.84%
2013-HK$5.41-1085.71%
2012HK$0.55

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
HK$10.27-80.48%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
HK$16.12-69.35%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
HK$221.28 320.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
HK$7.21-86.29%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
-HK$15.91-130.25%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
HK$27.44-47.84%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
-HK$234.41-545.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
HK$14.93-71.62%๐Ÿ‡ฌ๐Ÿ‡ง UK